Q&A with Jerry Jost - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Jerry Jost
The president of Jost Chemical talks about client demands, supplier audits, and more.

Pharmaceutical Technology
Volume 34, Issue 8, pp. 73

PharmTech:

Do you see a new industry trend emerging?

Jost:

One trend we see emerging is that pharmaceutical customers are demanding full traceability for their raw materials. They want to know the identity of the manufacturer of their raw materials. Other trends include an increase in requests for new custom products or modifications of existing products. Customers are beginning to demand materials that fit their processes; they no longer want to adapt their processes to the available materials. Being the manufacturer allows Jost to be flexible and respond to these requests by meeting specific impurity-limit requirements, special particle-size needs, and custom packaging requirements.

PharmTech:

What is the most common demand your clients are currently making of you?

Jost:

Currently, we are seeing an increase in customers requesting to audit our facility or have a third party audit our facility on their behalf. We do our best to balance our customers' audit requests and the costs incurred by Jost. Our department leaders participate in audits so that our customers have access to the people who know most about our processes. More and more, companies want to audit new suppliers before they use the latters' materials in production. Face-to-face meetings with customers allow our managers to learn more about their individual needs. These meetings are valuable to us because they help us maintain relationships with our clients.

PharmTech:

How do you stay abreast of new developments in the industry?

Jost:

I stay abreast of new developments in the industry by staying close to our customers. I personally read every sales-call report written by each of our salespeople. By doing so, I learn about trends, supply issues, and organizational changes. We make plans for new products and plant additions because of these sales reports, as well.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
24%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
15%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here